Taysha Gene Therapies, Inc. (TSHA)

NMS – Real vaqt narxi. Valyuta: USD

6.85

+0.03 (0.44%)

Yopilishda: May 12, 2026, 4:00 PM EDT

6.90

+0.05 (0.73%)

Bozor oldidan: May 13, 2026, 6:33 AM EDT

06.05.2026

Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript

06.05.2026

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.

01.05.2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, May 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees, in the aggregate, restricted stock units (RSUs) representing 188,000 shares of the Company's common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

29.04.2026

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM Eastern Time.

27.04.2026

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS by lumbar IT administration

03.04.2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, April 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 300,000 shares of the Company's common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

19.03.2026

Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

06.05.2026

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

01.05.2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03.04.2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19.03.2026

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026

Taysha Gene Therapies, Inc. (TSHA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

Search stocks

Taysha Gene Therapies, Inc. (TSHA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update